



Attorney Docket No.: 1049-1-030N

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Stevan R. Hubbard et al.

SERIAL NO.: 10/632,139

EXAMINER: Eric S. Dejong

DATE FILED: July 31, 2003

ART UNIT: 1631

FOR: METHODS FOR DESIGNING IGF1 RECEPTOR MODULATORS  
FOR THERAPEUTICS

**CERTIFICATE OF MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA on May 9, 2006.

Carolyn Di Meglio  
(Name of Depositor)

*Carolyn Di Meglio*  
(Signature and Date)

5/9/06

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **CA** through **CM** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

*Sarah J. Fashena*  
Sarah J. Fashena, Ph.D.  
Agent for Applicants  
Registration No. 57,600

KLAUBER & JACKSON LLC  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
(201) 487-5800

Date: May 9, 2006



PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office  LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT  <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTORNEY DOCKET NO.	1049-1-030N
	SERIAL NO.	10/632,139
	APPLICANT	Stevan R. Hubbard et al.
	FILING DATE	July 31, 2003
	GROUP	1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Favelyukis et al., Nature Structural Biology, 8:1058-1063 (2001)
	CB	Munshi et al., The Journal of Biological Chemistry, 277:38797-38802 (2002)
	CC	Pautsch et al., Structure, 9:955-965 (2001)
	CD	Whittaker et al., The Journal of Biological Chemistry, 276:43980-43986 (2001)
	CE	Li et al., Biochemical Pharmacology, 68:145-154 (2004)
	CF	Girrita et al., Cancer Research, 64:236-242 (2004)
	CG	Blum et al., The Journal of Biological Chemistry, 278:40442-40454 (2003)
	CH	Blum et al., Biochemistry, 39:15705-15712 (2000)
	CI	Wittman et al., J. Med. Chem., 48:5639-5643 (2005)

EXAMINER:

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	CJ	Garcia-Echeverria et al., Cancer Cell, 5:231-239 (2004)
	CK	Mitsiades et al., Cancer Cell, 5:221-230 (2004)
	CL	Bell et al., Biochemistry, 44:9430-9440 (2005)
	CM	Munshi et al., Acta Cryst, D 59:1725-1730 (2003)
EXAMINER:		DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		